Valsartan, Losartan & Irbesartan Contamination Settlement: Up to $120 if You Bought These Blood Pressure Meds — File by June 2, 2026
Valsartan, Losartan & Irbesartan Contamination Class Action Settlement
Three pharmaceutical manufacturers agreed to pay a combined $15.3 million to settle class action claims that their blood-pressure medications were contaminated with probable human carcinogens. If you paid out of pocket for Hetero Valsartan (May–July 2018), Aurobindo Irbesartan (Jan 2016–present), or specific lots of Vivimed Losartan, you may be eligible for a cash payment. The deadline to file a claim is June 2, 2026.
Settlement fund
$15.3M
Common fund
Top payout
Up to $120
Per consumer (Hetero Valsartan); pro rata for Aurobindo and Vivimed
Claim deadline
Jun 2, 2026
11 days remaining
You may be owed money
Filing is free and takes a few minutes. Deadline: Jun 2, 2026.
Do you qualify?
You are a Class Member if ALL of the following apply:
- Hetero Valsartan: You are an individual in the U.S. (including territories and possessions) who paid any amount for retail purchases of Valsartan finished drug formulations made with Hetero Process III Valsartan API, sold between May 1, 2018 and July 31, 2018.
- Aurobindo Irbesartan: You are an individual in the U.S. (including territories and possessions) who paid any amount for retail purchases of irbesartan finished drug formulations manufactured using Aurobindo’s IC Route of Synthesis API, purchased at any time from January 1, 2016 to the present.
- Vivimed Losartan: You are an individual in the U.S. (including territories and possessions) who paid any amount for retail purchases of Vivimed Losartan finished drug formulations sold under any of these specific NDC codes: 23155-644-09, 23155-644-10, 23155-645-03, 23155-645-09, 23155-645-10, 23155-646-03, 23155-646-09, or 23155-646-10.
- Excluded: Defendants and their affiliated entities, employees, officers, and directors; all federal and state governmental entities (except cities, towns, municipalities, or counties with self-funded prescription drug plans); Pharmacy Benefit Managers; plaintiffs’ and defendants’ counsel of record; any personal injury plaintiff or claimant in the MDL; and the presiding judge and their family members.
Not sure if you qualify? Call the Settlement Administrator at 1-866-875-9644, email info@SartanMedicationSettlement.com, or visit SartanMedicationSettlement.com.
What happened
Plaintiffs allege that the three settling defendants manufactured, distributed, and sold blood-pressure medications containing Valsartan, Irbesartan, and Losartan APIs that were contaminated with nitrosamine impurities, including N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA), and N-nitroso-N-methyl-4-aminobutyric acid (NMBA). The FDA classifies nitrosamines as probable human carcinogens. Plaintiffs claim the contamination caused them to pay for medications that did not deliver the quality represented, resulting in economic loss. The settlements cover three separate product lines: Hetero-branded Valsartan, Aurobindo-branded Irbesartan made via a specific synthesis route, and Vivimed-branded Losartan sold under specific NDC codes.
All three defendant groups deny any wrongdoing, deny that the levels of nitrosamine impurities in their products were or could be carcinogenic, and have asserted legal and factual defenses. The Court has not decided in favor of either side. The parties agreed to settle to avoid the cost, risk, and time of continued litigation. These settlements resolve economic loss claims only; they do not affect any personal injury claims pending in the same MDL.
How to file a claim
-
1. Confirm which medication you purchased
Check whether your prescription was Hetero Valsartan (May–July 2018), Aurobindo Irbesartan (Jan 2016–present via IC Route of Synthesis), or Vivimed Losartan (matching specific NDC codes above). Your pharmacy receipt, insurance Explanation of Benefits (EOB), or a call to your pharmacy can confirm the manufacturer and NDC. If you are unsure, the administrator can help at 1-866-875-9644.
-
2. Tally up your claim
For Hetero Valsartan: claims are calculated per 30-day supply. The default payment is up to $40 per 30-day supply, capped at $120 per consumer total. If you can document (via receipts or pharmacy records) that you paid more than $40 for a 30-day supply out of pocket, you may claim the higher amount without the $40 or $120 caps. For Aurobindo Irbesartan and Vivimed Losartan, the per-claimant amount will be determined pro rata once all valid claims are received; final amounts depend on total valid claims and the Court-approved allocation plan.
-
3. File online or by mail
Submit the Claim Form online at sartanmedicationsettlement.pnclassaction.com by June 2, 2026, or download and mail a paper Claim Form (postmarked by June 2, 2026) to: Sartan Medication Settlement Administrator, P.O. Box 3376, Baton Rouge, LA 70821. Include any supporting documentation if you have it, but documentation is not required to file; the administrator may follow up if it is needed to approve your claim.
-
4. Receive your payment
Payments will be issued after the Court grants final approval at the June 30, 2026 Fairness Hearing and any appeals are resolved. The appeal process can take a year or more. No follow-up is required once your claim is submitted.
Key dates
- Jun 2, 2026 Opt-out & objection deadline Upcoming
- Jun 2, 2026 Claim filing deadline Upcoming
- Jun 30, 2026 Final Fairness Hearing (10:00 a.m., in person (Courtroom 3D, Camden, NJ)) Upcoming
- TBD after final approval Payments issued to claimants Pending
The Fairness Hearing is scheduled for June 30, 2026 at 10:00 a.m. before Judge Robert B. Kugler in Courtroom 3D of the United States District Court for the District of New Jersey, Mitchell H. Cohen Building & U.S. Courthouse, 4th & Cooper Streets, Camden, NJ 08101. The Court may move the hearing without additional notice, so check SartanMedicationSettlement.com for updates before traveling.
Where the money is going
The three settlements together total approximately $15.3 million across separate common funds: $11,365,489.80 from Hetero, $2,000,000 from Aurobindo, and $1,899,000 from Vivimed. For Hetero, consumers are allocated up to 40% of the net fund (after attorneys’ fees, service awards, and administration costs); the remainder goes to third-party payors. For Aurobindo and Vivimed, the consumer/TPP split will be set by Class Counsel and approved by the Court before final approval.
All amounts are pending and subject to final court approval. For Hetero Valsartan, consumer payments are capped at $40 per 30-day supply ($120 total) unless you can document higher out-of-pocket costs; if total consumer claims exceed 40% of the net Hetero fund, all consumer payments will be reduced pro rata. Per-claimant amounts for Aurobindo and Vivimed are not yet determined and will be set by a Court-approved Plan of Allocation.
Common questions
How much money will I receive?
It depends on which medication you purchased. For Hetero Valsartan, the default payment is up to $40 per 30-day supply, with a $120 per-consumer cap. If you can document with pharmacy records that you paid more than $40 per supply out of pocket, those caps do not apply. For Aurobindo Irbesartan and Vivimed Losartan, the exact amount is not yet determined; it will be calculated pro rata among all eligible claimants after the Court approves a Plan of Allocation.
Do I need to submit proof of purchase?
Documentation is encouraged but not required to submit your claim. The administrator will review your form and may contact you later for proof of purchase from your pharmacy if it is needed to approve your claim. For Hetero Valsartan consumers seeking payments above the $40/$120 cap, pharmacy receipts or records documenting your actual out-of-pocket costs will be required.
What if I didn’t receive a notice?
Yes, you can still file a claim even if you did not receive a notice, as long as you meet the class definition for one of the three settlements. Notice was distributed by email, text message, and mail to known class members, and was also published on the settlement website. Visit SartanMedicationSettlement.com or call 1-866-875-9644 to verify your eligibility and submit a claim.
Does staying in the class affect my right to sue later?
By staying in the class, you give up the right to sue the settling defendants for economic loss claims related to the contaminated medications covered by your settlement. You can opt out by June 2, 2026 by mailing a signed written exclusion request to: Sartan Medication Settlement Administrator, ATTN: Exclusion Request, P.O. Box 3376, Baton Rouge, LA 70821, or by emailing it to info@SartanMedicationSettlement.com. Note: opting out means you cannot receive a payment from this settlement. These settlements do not release personal injury claims.
When will payments be sent out?
Payments will go out after the Court grants final approval at the June 30, 2026 Fairness Hearing and any appeals are resolved. Appeals can add a year or more to the timeline. No follow-up is required once your claim is submitted.
Dapeer Law, P.A.
Consumer class action attorneys based in South Florida. We track settlements so you don’t have to.
Similar open settlements
This page is for informational purposes only and does not constitute legal advice. Dapeer Law, P.A. is not the administrator of this settlement and is not affiliated with Hetero Drugs, Ltd., Hetero Labs Ltd., Hetero USA, Inc., and Camber Pharmaceuticals, Inc.; Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., and Aurolife Pharma LLC; Vivimed Life Sciences Pvt Ltd and Strides Pharma Science Limited, Sartan Medication Settlement Administrator (the Settlement Administrator), or Class Counsel John R. Davis of Slack Davis Sanger, LLP, Ruben Honik of Honik Law, and Conlee S. Whiteley of Kanner & Whiteley, LLC. The case is In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK (MDL No. 2875), pending in the U.S. District Court for the District of New Jersey before the Honorable Robert B. Kugler. Class representatives are Jacqueline Harris, Leland Gildner, Veronica Longwell, Peter O'Brien, Mark Hays, and James Childs. Hetero, Aurobindo, and Vivimed denies wrongdoing. This website is attorney advertising. Past results do not guarantee future outcomes.
